doi: 10.1080/10590501.2016.1278298
A larger uncertainty looms: If the Trump administration does not extend or replace the demonstration, obesity drug coverage will end in December 2027
Products are not medicines, not supplements, and not for human consumption
The effect is transient, and appears not to cause damage, probably because cell turnover in the gastric mucosa is rapidas observed following ethanol absorption in the stomach (263265)
Their efficacy in treating both AUD and metabolic disorders, including obesity and type 2 diabetes mellitus (T2DM), offers a compelling additional clinical rationale for their use [22, 23]
With shortage status removed, the primary legal basis that had permitted broad-scale compounding of these medications narrowed significantly